Laurus Labs 향후 성장

Future 기준 점검 4/6

Laurus Labs (는) 각각 연간 29.5% 및 11.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 28.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 16% 로 예상됩니다.

핵심 정보

29.5%

이익 성장률

28.82%

EPS 성장률

Pharmaceuticals 이익 성장	15.3%
매출 성장률	11.8%
향후 자기자본이익률	15.98%
애널리스트 커버리지	Good
마지막 업데이트	01 Aug 2025

최근 향후 성장 업데이트

Laurus Labs Limited Just Recorded A 7.2% EPS Beat: Here's What Analysts Are Forecasting Next

Apr 27

Laurus Labs Limited Beat Revenue Forecasts By 7.0%: Here's What Analysts Are Forecasting Next

Jan 27

Recent updates

Revenues Tell The Story For Laurus Labs Limited (NSE:LAURUSLABS) As Its Stock Soars 28%

Jul 20

Investors Shouldn't Be Too Comfortable With Laurus Labs' (NSE:LAURUSLABS) Earnings

Jun 11

Laurus Labs (NSE:LAURUSLABS) Has A Pretty Healthy Balance Sheet

May 19

Laurus Labs Limited Just Recorded A 7.2% EPS Beat: Here's What Analysts Are Forecasting Next

Apr 27

Laurus Labs Limited (NSE:LAURUSLABS) Not Flying Under The Radar

Apr 07

Laurus Labs Limited Beat Revenue Forecasts By 7.0%: Here's What Analysts Are Forecasting Next

Jan 27

CDMO Expansion May Impact Near-Term Margins But Pave Way For Future Revenue Streams

Jan 26 Heavy investment in CDMO and microbial precision initiatives may lead to revenue delays and short-term margin compression due to underutilized assets.

These 4 Measures Indicate That Laurus Labs (NSE:LAURUSLABS) Is Using Debt Extensively

Jan 25

이익 및 매출 성장 예측

NSEI:LAURUSLABS - 애널리스트 향후 추정치 및 과거 재무 데이터 (INR Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
3/31/2028	84,441	11,560	5,911	N/A	9
3/31/2027	75,174	8,832	3,042	N/A	13
3/31/2026	65,146	6,337	2,680	N/A	13
6/30/2025	59,286	5,088	N/A	N/A	N/A
3/31/2025	55,540	3,583	-393	6,017	N/A
12/31/2024	52,733	2,003	N/A	N/A	N/A
9/30/2024	50,532	1,311	-3,277	2,489	N/A
6/30/2024	50,540	1,482	N/A	N/A	N/A
3/31/2024	50,408	1,606	-126	6,657	N/A
12/31/2023	49,821	1,879	N/A	N/A	N/A
9/30/2023	53,320	3,678	2,870	12,248	N/A
6/30/2023	56,834	5,637	N/A	N/A	N/A
3/31/2023	60,406	7,901	37	9,939	N/A
12/31/2022	60,845	9,176	N/A	N/A	N/A
9/30/2022	55,684	8,683	13	8,393	N/A
6/30/2022	51,960	8,374	N/A	N/A	N/A
3/31/2022	49,356	8,275	343	9,111	N/A
12/31/2021	49,227	8,937	N/A	N/A	N/A
9/30/2021	51,823	10,128	-1,705	7,112	N/A
6/30/2021	51,177	10,532	N/A	N/A	N/A
3/31/2021	48,135	9,836	442	7,330	N/A
12/31/2020	42,407	7,971	N/A	N/A	N/A
9/30/2020	36,819	5,977	1,548	5,427	N/A
6/30/2020	32,555	4,120	N/A	N/A	N/A
3/31/2020	28,317	2,553	1,252	3,474	N/A
12/31/2019	26,277	1,883	N/A	N/A	N/A
9/30/2019	24,276	1,326	1,613	3,538	N/A
6/30/2019	23,035	923	N/A	N/A	N/A
3/31/2019	22,919	938	N/A	2,977	N/A
12/31/2018	22,170	957	N/A	N/A	N/A
9/30/2018	21,665	1,127	N/A	N/A	N/A
6/30/2018	21,168	1,453	N/A	N/A	N/A
3/31/2018	20,562	1,676	N/A	3,425	N/A
12/31/2017	19,687	1,917	N/A	N/A	N/A
9/30/2017	19,954	2,019	N/A	N/A	N/A
6/30/2017	19,733	2,014	N/A	N/A	N/A
3/31/2017	19,046	1,881	N/A	3,320	N/A
3/31/2016	17,776	1,337	N/A	1,820	N/A
3/31/2015	13,266	684	N/A	-647	N/A

애널리스트 향후 성장 전망

수입 대 저축률: LAURUSLABS 의 연간 예상 수익 증가율( 29.5% )이 saving rate( 6.8% 보다 높습니다. ).

수익 vs 시장: LAURUSLABS 의 연간 수익( 29.5% ) Indian 시장( 15.5% 보다 빠르게 성장할 것으로 예상됩니다. 15.5% 연간).

고성장 수익: LAURUSLABS 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: LAURUSLABS 의 수익(연간 11.8% ) Indian 시장( 9.8% 보다 빠르게 성장할 것으로 예상됩니다. 9.8% 연간).

고성장 수익: LAURUSLABS 의 수익(연간 11.8% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: LAURUSLABS 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 16 %).

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/08/08 11:21
종가	2025/08/08 00:00
수익	2025/06/30
연간 수익	2025/03/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Laurus Labs Limited는 23명의 분석가가 다루고 있습니다. 이 중 13명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Nitin Bhasin	Ambit Capital
null null	Antique Stockbroking Ltd.
Vijayaraghavan Swaminathan	Avendus Spark

Laurus Labs 향후 성장

Future 기준 점검 4/6

핵심 정보

최근 향후 성장 업데이트

Price target increased by 19% to ₹698

Laurus Labs Limited Just Recorded A 7.2% EPS Beat: Here's What Analysts Are Forecasting Next

Price target increased by 8.3% to ₹565

Price target increased by 14% to ₹512

Laurus Labs Limited Beat Revenue Forecasts By 7.0%: Here's What Analysts Are Forecasting Next

Consensus EPS estimates fall by 12%

Recent updates

Price target increased by 19% to ₹698

First quarter 2026 earnings: EPS and revenues exceed analyst expectations

Revenues Tell The Story For Laurus Labs Limited (NSE:LAURUSLABS) As Its Stock Soars 28%

Laurus Labs Limited to Report Q1, 2026 Results on Jul 25, 2025

Investors Shouldn't Be Too Comfortable With Laurus Labs' (NSE:LAURUSLABS) Earnings

Full year 2025 earnings: EPS and revenues exceed analyst expectations

New minor risk - Dividend sustainability

Laurus Labs (NSE:LAURUSLABS) Has A Pretty Healthy Balance Sheet

Laurus Labs Limited, Annual General Meeting, Jun 26, 2025

Laurus Labs Limited Just Recorded A 7.2% EPS Beat: Here's What Analysts Are Forecasting Next

Price target increased by 8.3% to ₹565

Full year 2025 earnings: EPS exceeds analyst expectations

Laurus Labs Limited Approves Interim Dividend for Financial Year 2024 - 2025, Payable on or After May 20, 2025

Laurus Labs Limited to Report Q4, 2025 Results on Apr 24, 2025

Laurus Labs Limited (NSE:LAURUSLABS) Not Flying Under The Radar

Price target increased by 14% to ₹512

Laurus Labs Limited Beat Revenue Forecasts By 7.0%: Here's What Analysts Are Forecasting Next

CDMO Expansion May Impact Near-Term Margins But Pave Way For Future Revenue Streams

Third quarter 2025 earnings: EPS in line with analyst expectations despite revenue beat

These 4 Measures Indicate That Laurus Labs (NSE:LAURUSLABS) Is Using Debt Extensively

Laurus Labs Limited to Report Q3, 2025 Results on Jan 24, 2025

Laurus Labs Limited's (NSE:LAURUSLABS) P/S Is On The Mark

Consensus EPS estimates fall by 12%

Laurus Labs (NSE:LAURUSLABS) Is Due To Pay A Dividend Of ₹0.40

First half dividend of ₹0.40 announced

Laurus Labs (NSE:LAURUSLABS) Takes On Some Risk With Its Use Of Debt

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

Laurus Labs Limited Approves Interim Dividend for the Financial Year 2024- 2025

Laurus Labs Limited to Report Q2, 2025 Results on Oct 24, 2024

Laurus Labs Limited Appoints Ramesh Subrahmanian as A Non-Executive Independent Director

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Laurus Labs Limited to Report Q1, 2025 Results on Jul 25, 2024

Laurus Labs Limited Announces Board Appointments

Full year 2024 earnings: EPS misses analyst expectations

Less than half of directors are independent

Less than half of directors are independent

Final dividend reduced to ₹0.40

Laurus Labs Limited, Annual General Meeting, Jul 11, 2024

Full year 2024 earnings: EPS misses analyst expectations

Laurus Labs Limited Approves Board Changes

Laurus Labs Limited to Report Q4, 2024 Results on Apr 25, 2024

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Laurus Labs Limited to Report Q3, 2024 Results on Jan 24, 2024

Consensus EPS estimates fall by 34%

Upcoming dividend of ₹0.40 per share at 0.4% yield

Price target increased by 7.2% to ₹371

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Laurus Labs Limited Approves Interim Dividend, Payable on or After November 09, 2023

Laurus Labs Limited to Report Q2, 2024 Results on Oct 20, 2023

Laurus Labs Limited (NSEI:LAURUSLABS) agreed to acquire an additional 14.54% stake in Laurus Bio Private Limited from one of the Promoters, non-executive director, his family members and few Employee/ex-Employee shareholders for approximately INR 720 million.

Investor sentiment improves as stock rises 16%

Consensus EPS estimates fall by 10%

New minor risk - Profit margin trend

First quarter 2024 earnings released: EPS: ₹0.46 (vs ₹4.68 in 1Q 2023)

Full year 2023 earnings: EPS and revenues miss analyst expectations

Laurus Labs Limited (NSEI:LAURUSLABS) signed an investment agreement to acquire additional 7.24% stake in Immunoadoptive Cell Therapy Private Limited for INR 800 million.

Upcoming dividend of ₹1.20 per share at 0.6% yield

Price target decreased by 11% to ₹382

Full year 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 10% to ₹470

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Laurus Labs Limited to Report Q3, 2023 Results on Jan 30, 2023

Insufficient new directors

Upcoming dividend of ₹0.80 per share

Price target decreased to ₹574

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorated over the past week

Full year 2022 earnings: Revenues and EPS in line with analyst expectations